12 search results for: symposium

Missing material
Content temporarily unavailable
ADVENT at IRS-ISIAN | The Importance of Understanding Smell Loss and Congestion in CRSwNP

Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.

Missing material
Content temporarily unavailable
ADVENT at IRS-ISIAN | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

Join Profs. Shigeharu Fujieda, Peter Hellings, and Eugenio De Corso for an educational symposium on the evolving understanding of disease control and clinical remission in CRSwNP.

Missing material
Content temporarily unavailable
ADVENT at WCPD 2025

The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.

Missing material
Content temporarily unavailable
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: ​ Going Beyond Symptom Control​

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

Missing material
Content temporarily unavailable
ADVENT at WCI 2025

Join ADVENT for an educational symposium on PN at WCI 2025!

Missing material
Content temporarily unavailable
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

Missing material
Content temporarily unavailable
ADVENT at NAPNAP 2025

Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.

Missing material
Content temporarily unavailable
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

Missing material
Content temporarily unavailable
ADVENT at ERS 2024

The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.

Missing material
Content temporarily unavailable
ADVENT at EADV 2024

Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.

 

Missing material
Content temporarily unavailable
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

Missing material
Content temporarily unavailable
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis

This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.